.Attributes Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after an average consequence of 11 months, clients along with metastatic stomach tumors that acquired biomarker-matched therapies based on distributing lump DNA profiling showed a better professional benefit than those receiving unmatched treatment.